Stevanato Group (NYSE:STVN) Stock Price Target Cut by UBS Group

Key Points

• UBS cut its price target on Stevanato Group to $16 from $23 and maintained a Neutral rating. Citi also lowered its target, while William Blair downgraded the stock to Market Perform.
• Third-quarter revenue rose 8% year over year to €326.1 million, but management expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes tied to one customer.
• Shares fell 5.8% on Wednesday. Despite the recent analyst actions, the stock’s consensus rating remains Moderate Buy.

Stevanato Group (NYSE:STVN - Get Free Report) had its price objective reduced by UBS Group from $23.00 to $16.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a "neutral" rating on the stock.

A number of other equities research analysts also recently weighed in on STVN. Weiss Ratings raised shares of Stevanato Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, August 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Stevanato Group in a research note on Wednesday, October 7th. They issued a "hold" rating on the stock. Citigroup dropped their target price on shares of Stevanato Group from $26.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday. Finally, William Blair lowered shares of Stevanato Group from an "outperform" rating to a "market perform" rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy".

Stevanato Group Stock Down 5.8%

Shares of STVN stock traded down €0.81 during trading hours on Wednesday, reaching €13.29. The company had a trading volume of 4,406,642 shares, compared to its average volume of 535,738. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.08 and a current ratio of 1.61. The stock's fifty day simple moving average is €20.35 and its 200 day simple moving average is €18.11. The company has a market capitalization of $4.02 billion, a P/E ratio of 23.72, a price-to-earnings-growth ratio of 1.62 and a beta of 0.80. Stevanato Group has a twelve month low of €12.05 and a twelve month high of €27.00.

Stevanato Group (NYSE:STVN - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing analysts' consensus estimates of €0.17 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. The firm had revenue of €326.06 million for the quarter. As a group, sell-side analysts expect that Stevanato Group will post 0.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Stevanato Group

In other Stevanato Group news, Director Elisabetta Magistretti sold 2,045 shares of Stevanato Group stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of €20.09, for a total value of €41,084.05. Following the completion of the sale, the director directly owned 2,930 shares in the company, valued at €58,863.70. The trade was a 41.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Marco Dal Lago sold 4,209 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of €20.09, for a total value of €84,558.81. Following the transaction, the chief financial officer owned 81,144 shares in the company, valued at approximately €1,630,182.96. This trade represents a 4.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 21,926 shares of company stock worth $459,738 in the last ninety days.

Institutional Investors Weigh In On Stevanato Group

Institutional investors and hedge funds have recently made changes to their positions in the company. State of Wyoming acquired a new stake in shares of Stevanato Group in the third quarter valued at approximately $75,000. Schwartz Investment Counsel Inc. boosted its holdings in Stevanato Group by 15.0% during the third quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company's stock worth $13,871,000 after purchasing an additional 86,385 shares during the last quarter. PineStone Asset Management Inc. grew its position in Stevanato Group by 8.4% in the third quarter. PineStone Asset Management Inc. now owns 41,335 shares of the company's stock valued at $867,000 after purchasing an additional 3,200 shares in the last quarter. Fenimore Asset Management Inc bought a new position in Stevanato Group in the third quarter valued at $12,212,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Stevanato Group in the 2nd quarter valued at $59,000.

More Stevanato Group News

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% year over year to €326.1 million. A valuation commentary also argued the shares could be undervalued following the results. Stevanato Group Q3 results Valuation commentary
• Neutral Sentiment: Several law firms announced investigations into whether Stevanato’s disclosures complied with securities laws. These are investigations, not findings of wrongdoing, and follow the company’s recent results and market reaction. Investigation announcement
• Negative Sentiment: Management said GLP-1-related revenue declined in Q3 and represented about 17%–18% of total revenue. The company expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes tied to one customer—raising concerns about a key source of demand. 2027 outlook and GLP-1 volumes
• Negative Sentiment: Analysts reduced expectations: Citi cut its price target to $20 from $26 but kept a Buy rating; UBS lowered its target to $16 from $23 and maintained Neutral; William Blair downgraded the stock to Market Perform from Outperform. UBS target cut William Blair downgrade

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.